SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing ...

Data from pivotal Phase 3 trial in CHB-associated liver fibrosis expected in Q2 2025Commercial launch in the PRC of generic nintedanib for the ...

"2025 is shaping up to be a pivotal year for Gyre across both our commercial-stage and clinical-stage portfolios. We plan to expand and enhance our commercial product offerings through the additions ...

It is estimated that about 85 per cent of evaporation across the globe occurs over the oceans ... the position of atmospheric winds and the shapes of the ocean basins. This 'gyre' circulation is ...

Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $10.70, but opened at $12.43. Gyre Therapeutics shares ...

Gyre Therapeutics, Inc. (NASDAQ:GYRE – Free Report) – Stock analysts at Noble Financial issued their FY2024 earnings per share (EPS) estimates for Gyre Therapeutics in a research report issued ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Warframe's Techrot Encore is here, and it is easily the biggest Echoes update in the history of the game. It's focused on improving Hollvania content, as expected of an Echoes update, bringing ...